Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AXT Inc (AXTI) vs Johnson & Johnson (JNJ) Price & Performance

Johnson & JohnsonTrade

Price performance (Past 24H)

Key statistics

AXT Inc vs Johnson & Johnson — how do they compare? AXT Inc trades at $79.2 (market cap $4.83B), while Johnson & Johnson trades at $260.76 (market cap $626.09B). The key difference: Johnson & Johnson is far larger — about 129.6× AXT Inc's market cap, and Johnson & Johnson pays a 2.06% dividend while AXT Inc pays none. Which is the better fit depends on your goals.

AXTIJNJ
Market Cap
$4.83B$626.09B
Sector
TechnologyHealth
52-Week High
$140.83$267.24
52-Week Low
$2.05$172.78
Enterprise Value
$4.50B$654.37B
Volume
6,156,228
Dividend Yield
2.06%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AXT Inc

AXTI is trading at $76.84, up 4.11% with strong bullish momentum following better-than-expected Q2 2026 earnings. The stock shows bullish technical signals with support at $72 and resistance at $77. Recent financials indicate a turnaround with Q2 EPS of $0.19 beating estimates and revenue growth driven by record indium phosphide demand for AI data centers.

The outlook appears positive with strong AI-driven demand and capacity expansion plans, though valuation metrics remain elevated with P/S of 30.53. Key risks include execution challenges in meeting demand and competitive pressures in the semiconductor substrate market. Analyst consensus is strongly bullish with 73% buy ratings and $72.50 price target.

Johnson & Johnson

Johnson & Johnson (JNJ) trades at $261.26, down 0.21% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and recent earnings beats. Revenue grew to $94.19B in 2025, with a net income margin of 21.48%, though cash flow turned negative due to heavy investing. The company maintains a robust dividend history, with consistent payouts and a 64-year growth streak.

Outlook remains positive with a consensus price target of $284.50, offering ~9% upside. Risks include legal headwinds and patent expirations, but analyst sentiment is bullish (52.5% buy ratings). JNJ's defensive profile and pipeline strength support long-term growth, though investors should monitor debt levels, which rose to 24.06% of assets in 2025.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AXT Inc

AXT develops and manufactures high-performance compound semiconductor wafer substrates. Its products, like indium phosphide and gallium arsenide, are essential for data centers, 5G, and consumer electronics.

Read more on AXTI

About Johnson & Johnson

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.

Read more on JNJ